Green Planet Bioengineering, Inc. (OTCMKTS:GPLB) is a biotechnology company specializing in the development of advanced tissue-engineering solutions for research and therapeutic applications. The company focuses on creating three-dimensional, biomimetic scaffolds that support cell growth and differentiation, enabling more accurate in vitro models for drug discovery, regenerative medicine, and personalized healthcare. Utilizing a combination of synthetic polymers and naturally derived biomaterials, Green Planet aims to bridge the gap between traditional two-dimensional cell cultures and complex biological systems.
At the core of Green Planet’s offerings are its proprietary scaffold platforms, which include collagen-based matrices and hyaluronic acid composites designed to emulate the extracellular environment of human tissues. These products are tailored to a range of cell types, from stem cells to primary cells, and are compatible with high-throughput screening workflows. In addition to off-the-shelf scaffold kits, Green Planet provides custom contract development services, working closely with pharmaceutical firms, academic institutions, and contract research organizations to design models for oncology, neurology, and cardiology studies.
Founded in 2014 by a team of biomedical engineers and life-science entrepreneurs, Green Planet has expanded its operations across North America, Europe, and Asia. The company’s research and manufacturing facilities include a primary headquarters in Massachusetts, a production laboratory in the Netherlands, and a joint-venture centre in Singapore. Over the past decade, Green Planet has forged strategic partnerships with leading universities and biopharma companies, securing collaborative grants to advance three-dimensional tissue constructs and organoid technologies.
Green Planet’s leadership team brings together seasoned executives and scientific experts. Chief Executive Officer Dr. Jennifer Chen has over 20 years of experience in regenerative medicine, while President and Chief Operating Officer Dr. Samuel Ng co-founded the company after a tenure in academic tissue-engineering research. Chief Financial Officer Michael Lee oversees capital strategy and corporate finance, supported by a board of directors that includes industry veterans in biomanufacturing and pharmaceutical development. Together, this team guides Green Planet’s mission to deliver next-generation bioengineering solutions to the global life-sciences community.
AI Generated. May Contain Errors.
Free GPLB Stock Alerts